These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 10499191)

  • 1. Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART).
    Vigouroux C; Gharakhanian S; Salhi Y; Nguyen TH; Chevenne D; Capeau J; Rozenbaum W
    Diabetes Metab; 1999 Sep; 25(3):225-32. PubMed ID: 10499191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beta-cell dysfunction and low insulin clearance in insulin-resistant human immunodeficiency virus (HIV)-infected patients with lipodystrophy.
    Haugaard SB; Andersen O; Vølund A; Hansen BR; Iversen J; Andersen UB; Nielsen JO; Madsbad S
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):354-61. PubMed ID: 15730419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperproinsulinaemia in normoglycaemic lipodystrophic HIV-infected patients.
    Haugaard SB; Andersen O; Hales CN; Halsall I; Rosenfalck AM; Iversen J; Madsbad S
    Eur J Clin Invest; 2006 Jun; 36(6):436-45. PubMed ID: 16684128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of apolipoproteins C3 and E with metabolic changes in HIV-infected adults treated with a protease-inhibitor-containing antiretroviral therapy.
    Bard JM; Lassalle R; Capeau J; Bach-Ngohou K; Nazih-Sanderson F; Rémy G; Reynes J; Ecobichon JL; Savès M; Raffi F;
    Antivir Ther; 2006; 11(3):361-70. PubMed ID: 16759053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired proinsulin secretion before and during oral glucose stimulation in HIV-infected patients who display fat redistribution.
    Haugaard SB; Andersen O; Halsall I; Iversen J; Hales CN; Madsbad S
    Metabolism; 2007 Jul; 56(7):939-46. PubMed ID: 17570256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced glucagon-like peptide-1 (GLP-1) response to oral glucose in glucose-intolerant HIV-infected patients on antiretroviral therapy.
    Andersen O; Haugaard SB; Holst JJ; Deacon CF; Iversen J; Andersen UB; Nielsen JO; Madsbad S
    HIV Med; 2005 Mar; 6(2):91-8. PubMed ID: 15807714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disorders of glucose metabolism in patients infected with human immunodeficiency virus.
    Dubé MP
    Clin Infect Dis; 2000 Dec; 31(6):1467-75. PubMed ID: 11096014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 protease inhibitors induce an increase of triglyceride level in HIV-infected men without modification of insulin sensitivity: a longitudinal study.
    Petit JM; Duong M; Duvillard L; Piroth L; Grappin M; Verges B; Chavanet P; Brun JM; Portier H
    Horm Metab Res; 2000 Sep; 32(9):367-72. PubMed ID: 11014386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Important differences in components of the metabolic syndrome between HIV-patients with and without highly active antiretroviral therapy and healthy controls.
    Bergersen BM; Schumacher A; Sandvik L; Bruun JN; Birkeland K
    Scand J Infect Dis; 2006; 38(8):682-9. PubMed ID: 16857615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protease therapy and changes to insulin and glucose.
    TreatmentUpdate; 1999 Jun; 11(4):5-6. PubMed ID: 11366792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor.
    Rakotoambinina B; Médioni J; Rabian C; Jubault V; Jais JP; Viard JP
    J Acquir Immune Defic Syndr; 2001 Aug; 27(5):443-9. PubMed ID: 11511820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
    Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
    AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy.
    Andersen O; Eugen-Olsen J; Kofoed K; Iversen J; Haugaard SB
    J Med Virol; 2008 Feb; 80(2):209-16. PubMed ID: 18098145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of association between dyslipidemia and insulin resistance in HIV-infected persons treated with highly active antiretroviral therapy.
    Swanson B; Keithley JK; Zeller JM; Sha BE
    Nutrition; 2004; 20(11-12):1022-5. PubMed ID: 15561494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients.
    Calza L; Manfredi R; Chiodo F
    J Antimicrob Chemother; 2004 Jan; 53(1):10-4. PubMed ID: 14645323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
    Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
    HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of metformin or gemfibrozil on the lipodystrophy of HIV-infected patients receiving protease inhibitors.
    Martínez E; Domingo P; Ribera E; Milinkovic A; Arroyo JA; Conget I; Pérez-Cuevas JB; Casamitjana R; de Lazzari E; Bianchi L; Montserrat E; Roca M; Burgos R; Arnaiz JA; Gatell JM
    Antivir Ther; 2003 Oct; 8(5):403-10. PubMed ID: 14640387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Adipokines and highly active antiretroviral therapy related lipodystrophy: clinical study of 52 cases].
    Tao MM; Zhang L; Qiu ZF; Xie J; Han Y; Yu W; Li M; Li TS
    Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(13):867-71. PubMed ID: 19671283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.